Caribou Biosciences is halting allogeneic CAR-T therapy programs after failing to secure enough capital to advance them. The biotech said it is reviewing strategic alternatives, a setback for a pipeline that recently spotlighted vispa-cel.
published
Caribou Biosciences is halting allogeneic CAR-T therapy programs after failing to secure enough capital to advance them. The biotech said it is reviewing strategic alternatives, a setback for a pipeline that recently spotlighted vispa-cel.
Latest documented BWB result
$NVDA market result
Exit $NVDA with $3 profit per share
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.